252 related articles for article (PubMed ID: 30806308)
1. Phytosterols and Triterpenoids for Prevention and Treatment of Metabolic-related Liver Diseases and Hepatocellular Carcinoma.
Sánchez-Crisóstomo I; Fernández-Martínez E; Cariño-Cortés R; Betanzos-Cabrera G; Bobadilla-Lugo RA
Curr Pharm Biotechnol; 2019; 20(3):197-214. PubMed ID: 30806308
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
3. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease.
Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291
[TBL] [Abstract][Full Text] [Related]
5. The Natural Course of Non-Alcoholic Fatty Liver Disease.
Calzadilla Bertot L; Adams LA
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
[TBL] [Abstract][Full Text] [Related]
6. Insights into the Role of PPARβ/δ in NAFLD.
Chen J; Montagner A; Tan NS; Wahli W
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129
[TBL] [Abstract][Full Text] [Related]
7. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
9. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
Salomone F; Godos J; Zelber-Sagi S
Liver Int; 2016 Jan; 36(1):5-20. PubMed ID: 26436447
[TBL] [Abstract][Full Text] [Related]
10. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
[TBL] [Abstract][Full Text] [Related]
12. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
Malnick SDH; Alin P; Somin M; Neuman MG
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
14. Anti-hepatocellular carcinoma activity and mechanism of chemopreventive compounds: ursolic acid derivatives.
Huang Q; Chen H; Ren Y; Wang Z; Zeng P; Li X; Wang J; Zheng X
Pharm Biol; 2016 Dec; 54(12):3189-3196. PubMed ID: 27564455
[TBL] [Abstract][Full Text] [Related]
15. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
16. Triterpenoids principle of Wedelia calendulacea attenuated diethynitrosamine-induced hepatocellular carcinoma via down-regulating oxidative stress, inflammation and pathology via NF-kB pathway.
Verma A; Singh D; Anwar F; Bhatt PC; Al-Abbasi F; Kumar V
Inflammopharmacology; 2018 Feb; 26(1):133-146. PubMed ID: 28608141
[TBL] [Abstract][Full Text] [Related]
17. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654
[TBL] [Abstract][Full Text] [Related]
18. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
20. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?
Scalera A; Tarantino G
World J Gastroenterol; 2014 Jul; 20(28):9217-28. PubMed ID: 25071314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
